Luciferase Reporter Cell Line - T47D

T47D is a comprehensively characterized human breast cancer cell line originally isolated from a metastatic pleural effusion of a 54-year-old female patient with an infiltrating ductal carcinoma. Growing as an adherent epithelial monolayer, T47D is highly valued in oncology research because it represents the classic luminal A subtype of breast cancer. It natively expresses robust levels of both estrogen receptors (ER) and progesterone receptors (PR), while also harboring a well-documented missense mutation in the TP53 gene. The Luciferase Reporter Cell Line - T47D builds upon this foundational endocrinological model by stably integrating the firefly luciferase gene into the cellular genome. This precise engineering enables the cells to constitutively express the luciferase enzyme, producing a highly reliable and quantifiable bioluminescent signal upon exposure to the standard substrate, D-luciferin. Crucially, the genetic modification is carefully designed to preserve the essential biological properties of the parental line. The engineered reporter cells strictly maintain their characteristic morphology, complex mutational signature, and, most importantly, their hallmark sensitivity to estrogenic stimulation, providing a biologically authentic and highly reliable model for hormone-dependent breast cancer research.

The functional integration of the firefly luciferase reporter transforms the T47D cell line into an indispensable asset for both rigorous in vitro analytics and advanced preclinical animal modeling. In standard laboratory environments, the continuous bioluminescent output serves as a highly sensitive, continuous metric for quantifying cell proliferation, monitoring metabolic viability, and conducting high-throughput drug screening. It is particularly ideal for evaluating the precise cellular responses to novel endocrine therapies, such as selective estrogen receptor modulators (SERMs) or selective estrogen receptor degraders (SERDs). When implanted orthotopically into the mammary fat pad of immunodeficient mice—often requiring exogenous estrogen supplementation to support robust engraftment—the continuous light emission facilitates highly sensitive, non-invasive bioluminescence imaging (BLI). This advanced capability empowers researchers to visually map localized tumor formation in real-time, pinpoint microscopic metastatic dissemination to secondary organs, and dynamically evaluate the long-term therapeutic efficacy of experimental anti-cancer treatments in living subjects, drastically reducing the reliance on destructive endpoint analyses.